Plexxikon Inc. v. Novartis Pharmaceuticals Corporation

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 PLEXXIKON INC., Case No. 17-cv-04405-HSG

Plaintiff, ORDER DENYING DEFENDANT’S

MOTION FOR LEAVE TO FILE

v. SECOND SUMMARY JUDGMENT

MOTION

NOVARTIS PHARMACEUTICALS CORPORATION, Re: Dkt. No. 345 11 Defendant.

Defendant Novartis Pharmaceuticals Corporation (“Novartis”) seeks leave to file a second summary judgment motion. Dkt No. 345 (“Mot.”). The deadline for dispositive motions has passed and the case is scheduled for trial in June 2020. Nevertheless, Novartis argues that the Federal Circuit’s recent decision in Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., 941 F.3d 1149 (Fed. Cir. 2019), constitutes intervening law and provides good cause to deviate from the scheduling and standing orders. The Court finds this matter appropriate for disposition without oral argument and the matter is deemed submitted. See Civil L.R. 7-1(b).” For the reasons detailed below, the Court DENIES the motion. …